ReviewInternational journal of urology : official journal of the Japanese Urological Association2025
Perirenal Fat in Disease Progression: From Inflammatory Mediator to Therapeutic Target.
Review in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease.Journal of clinical medicine · 2026Article
- Perirenal Fat and Disrupted Circadian Blood Pressure Patterns.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Article
- Study on the prediction of postoperative metastasis in renal cancer using perirenal fat CT radiomics combined with clinical features.Frontiers in oncology · 2026Article
- Ectopic lipid deposition in kidney diseases: mechanisms in specific cell types and therapeutic strategies.Frontiers in endocrinology · 2026Review
- Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.Journal of kidney cancer and VHL · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Perirenal fat (PRF), the adipose tissue that encases the kidneys, has long been considered a passive energy reservoir and mechanical buffer. However, emerging evidence has identified PRF as a biologically active visceral fat depot that secretes adipocytokines, inflammatory mediators, and other bioactive molecules, and thereby contributes to the pathogenesis and progression of several systemic diseases. PRF is associated with renal cell carcinoma, cardiovascular disease, chronic kidney disease, obesity, and metabolic syndrome. In renal cell carcinoma, PRF thickness correlates positively with tumor stage and negatively with prognosis. In cardiovascular and renal disorders, PRF accumulation is linked to elevated blood pressure and impaired renal function. Furthermore, PRF promotes a pro-inflammatory microenvironment that exacerbates chronic kidney disease and metabolic abnormalities. These findings underscore the clinical relevance of PRF, both as a diagnostic and prognostic marker and a potential target for therapeutic intervention. This review provides a comprehensive overview of the roles of PRF in disease development and progression and emphasizes its emerging significance in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.